dc.creator | Parés, Albert | es |
dc.creator | Albillos, Agustín | es |
dc.creator | Andrade, Raúl Jesús | es |
dc.creator | Berenguer, Marina | es |
dc.creator | Crespo, Javier | es |
dc.creator | Romero Gómez, Manuel | es |
dc.creator | Vergara, Mercè | es |
dc.creator | Vendrell, Belén | es |
dc.creator | Gil, Alicia | es |
dc.date.accessioned | 2024-05-16T13:19:35Z | |
dc.date.available | 2024-05-16T13:19:35Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Parés, A., Albillos, A., Andrade, R.J., Berenguer, M., Crespo, J., Romero Gómez, M.,...,Gil, A. (2018). Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. Revista Española de Enfermedades Digestivas, 110 (10), 641-649. https://doi.org/10.17235/reed.2018.5665/2018. | |
dc.identifier.issn | 1130-0108 | es |
dc.identifier.issn | 2340-4167 | es |
dc.identifier.uri | https://hdl.handle.net/11441/158458 | |
dc.description.abstract | Introduction: primary biliary cholangitis (PBC) is a rare
disease with limited data regarding its epidemiology and
standard clinical management in Spain.
Objective: to gain insight into the epidemiology, patient
f
low, diagnosis, follow-up and treatment of PBC in Spain.
Methods: a review of the literature and Delphi study involv
ing 28 specialists in two rounds of consultations and an
in-person results validation workshop.
Results: there are approximately 9,400 patients with PBC in
Spain, with an annual incidence of 0.51-3.86 cases/100,000
population. Albeit, a high error margin may be presumed
due to the scarcity of relevant studies on this subject. Sev
eral months may elapse from suspicion to a confirmed
diagnosis, usually by a gastroenterologist or hepatologist.
The role of the liver biopsy for diagnosis and follow-up is
heterogeneous. Overall, 95% of patients are treated with
ursodeoxycholic acid (UDCA) and response is primarily
monitored using the Barcelona criteria. Follow-up is per
formed every six months, with a heterogeneous use of
the various available techniques. No recommendations or
second-line commercial drugs are available in the case of
no response, inadequate response or intolerance to UDCA.
Conclusions: while epidemiology may be estimated based
on expert opinions, national registries are needed to pro
vide accurate, up-to-date information on epidemiologi
cal parameters, disease stage and response to treatment
in patients with PBC. Furthermore, novel therapies are
required for selected patient groups. | es |
dc.format | application/pdf | es |
dc.format.extent | 9 p. | es |
dc.language.iso | eng | es |
dc.publisher | Aran Ediciones S.A. | es |
dc.relation.ispartof | Revista Española de Enfermedades Digestivas, 110 (10), 641-649. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Primary biliary cholangitis | es |
dc.subject | Epidemiology | es |
dc.subject | Diagnosis | es |
dc.subject | Treatment | es |
dc.title | Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.reed.es/ArticuloFicha.aspx?id=3370&hst=0&idR=65&tp=1 | es |
dc.identifier.doi | 10.17235/reed.2018.5665/2018 | es |
dc.contributor.group | Universidad de Sevilla. CTS532: Unidad de Hepatología (Sistema Sanitario Público de Andalucía. Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla) | es |
dc.journaltitle | Revista Española de Enfermedades Digestivas | es |
dc.publication.volumen | 110 | es |
dc.publication.issue | 10 | es |
dc.publication.initialPage | 641 | es |
dc.publication.endPage | 649 | es |